市場調查報告書
商品編碼
1468010
關節內粘稠補充療法市場:按產品、來源、應用和最終用途 - 全球預測 2024-2030Viscosupplementation Market by Product (Five Injection, Single Injection, Three Injection), Source (Animal, Non-animal), Application, End-use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年關節內粘稠補充療法市場規模為28.3億美元,預計2024年將達30.1億美元,2030年將達43.2億美元,複合年成長率為6.19%。
關節內粘稠補充療法是一種將透明質酸注射到關節(例如膝蓋)的醫療程序,以緩解骨關節炎等疾病引起的疼痛。作為一種非手術治療選擇,關節內粘稠補充療法旨在改善關節功能、減輕疼痛,並可能延遲關節重建手術。關節疾病和運動相關損傷的增加、更容易患這些疾病的老年人數量的增加以及對微創手術的日益偏好是市場成長的主要因素。然而,包括類固醇注射和非藥物治療在內的替代治療方案的存在可能會阻礙市場的成長。然而,透明質酸配方和輸送的技術進步以及醫療保健基礎設施的改善預計將為開拓關節內粘稠補充療法市場創造潛在機會。
主要市場統計 | |
---|---|
基準年[2023] | 28.3億美元 |
預測年份 [2024] | 30.1億美元 |
預測年份 [2030] | 43.2億美元 |
複合年成長率(%) | 6.19% |
產品採用三次注射方案來減輕骨關節炎患者的疼痛和改善活動能力的情況正在迅速增加。
5 次注射方案是一種關節內粘稠補充療法,由 5 次透明質酸 (HA) 注射組成。此療程通常每週進行一次,連續5週。它主要用於治療膝骨關節炎,旨在恢復關節內滑液的潤滑性和緩衝性能。單次注射方案提供了單次注射的便利,作為關節內粘稠補充療法的替代方法。這些產品由高濃度的透明質酸配製而成,通常含有交聯劑,可提高關節內治療的耐久性和壽命。三次注射方案是一種廣泛採用的關節內粘稠補充療法,涉及一系列三次透明質酸注射。這些通常每週進行一次,旨在補償關節間隙滑液的黏度。這種治療的主要目標是減輕骨關節炎患者的疼痛並增加活動能力。三次注射方案在更廣泛的五次注射療程和單次注射治療方案之間取得了平衡,在治療承諾和症狀緩解持續時間方面提供了中間位置。
對非動物性透明質酸的來源偏好增加,以消除過敏反應的風險
動物源性透明質酸是獲得用於關節內粘稠補充療法的透明質酸的主要資訊。動物源利用富含透明質酸的公雞冠組織或從其他鳥類的組織中提取。非動物源性透明質酸是透過細菌發酵過程產生的。獸疫鏈球菌等基因工程菌株用於生物合成高純度的透明質酸。非動物HA被認為是安全有效的,消除了與禽類蛋白相關的可能引起過敏反應的風險。此外,由於道德考量和生產一致性,非動物性透明質酸越來越受歡迎。
應用實例關節內粘稠補充療法治療膝骨關節炎的先進應用
手腕關節的關節內粘稠補充療法包括將透明質酸直接注射到受影響的關節中。當傳統的非手術治療(例如止痛藥和物理治療)不夠有效時,可以使用這種治療方法。關節內粘稠補充療法手腕關節的主要好處在於減輕疼痛,進而改善功能和生活品質。關節內粘稠補充療法已被證明是治療方法,特別是那些對傳統治療方法沒有反應的患者。髖關節手術較為複雜,由於髖關節位置較深,通常需要超音波或 X 光導引。與長期使用非類固醇消炎劑(NSAID)相比,關節內粘稠補充療法髖骨關節炎的主要優點是其安全性更高。膝骨關節炎最常使用的是關節內粘稠補充療法。由於膝關節是主要的負重關節,因此非常容易磨損。關節內粘稠補充療法程序旨在恢復因膝骨關節炎而損失的滑液的自然特性。
擴大關節內粘稠補充療法在最終整形外科診所/門診手術中心 (ASC) 中的使用
醫院是關節內粘稠補充療法內替代療法是骨關節炎(尤其是膝關節)患者的一種治療選擇。醫院作為採用多學科方法的綜合醫療機構,對於提供這種微創手術至關重要。關節內粘稠補充療法包括將透明質酸注射到關節中以潤滑關節、緩解疼痛並改善活動能力。整形外科診所和門診手術中心 (ASC) 是經常進行關節內粘稠補充療法的特殊最終使用環境。由於這些中心專注於肌肉骨骼健康,因此非常適合提供關節內粘稠補充療法等針對性治療。 ASC 的便利性、效率和普遍較低的成本使其成為尋求門診治療的患者的有吸引力的選擇。
區域洞察
由於骨關節炎盛行率不斷上升、醫療保健成本不斷上升、人們對微創治療的偏好增加以及 FDA 批准的 HA 產品的普及,美洲市場正在不斷發展。先進的醫療保健系統、對骨關節炎治療選擇的認知不斷提高以及支持性法律規範正在推動歐洲關節內粘稠補充療法市場的成長。由於治療方法的可用性和可負擔性的提高以及骨關節炎競爭性治療方法的普及,中東和非洲的關節內粘稠補充療法市場正在不斷成長。由於骨關節炎的高發生率、不斷擴大的醫療基礎設施以及越來越多的先進骨關節炎治療方法,亞太地區對關節內粘稠補充療法的需求很高。此外,提高關節內粘稠補充療法療效的持續研究預計將推動全球對關節內粘稠補充療法市場的需求。
FPNV定位矩陣
FPNV定位矩陣對於評估關節內粘稠補充療法市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對關節關節內粘稠補充療法市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,從而在市場上獲得競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.關節內粘稠補充療法市場的市場規模與預測為何?
2.在關節內粘稠補充療法市場的預測期間內,有哪些產品、細分市場、應用和領域需要考慮投資?
3.關節內粘稠補充療法市場的技術趨勢和法規結構是什麼?
4.關節內粘稠補充療法市場主要供應商的市場佔有率為何?
5. 進入關節內粘稠補充療法市場的合適型態和策略手段是什麼?
[184 Pages Report] The Viscosupplementation Market size was estimated at USD 2.83 billion in 2023 and expected to reach USD 3.01 billion in 2024, at a CAGR 6.19% to reach USD 4.32 billion by 2030.
Viscosupplementation is a medical procedure involving the injection of hyaluronic acid into a joint, such as the knee, to relieve pain caused by conditions such as osteoarthritis. As a non-surgical treatment option, viscosupplementation aims to improve joint function, reduce pain, and possibly delay joint replacement surgery. Increasing incidences of joint disorders and sport-related injuries, a growing elderly population that is more susceptible to such ailments, and the rising preference for minimally invasive procedures significantly contribute to market growth. However, the existence of alternative treatment options, including steroid injections and non-pharmacologic therapies, may impede market growth. Nevertheless, technological advancements in formulating and delivering hyaluronic acid and healthcare infrastructure improvements are expected to create potential opportunities for developing the viscosupplementation market.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.83 billion |
Estimated Year [2024] | USD 3.01 billion |
Forecast Year [2030] | USD 4.32 billion |
CAGR (%) | 6.19% |
Products: Burgeoning adoption of a three-injection regimen to reduce pain and enhance mobility in patients with osteoarthritis
The five-injection regimen is a viscosupplementation treatment consisting of five hyaluronic acid (HA) injections. This course of therapy is typically administered once per week over five consecutive weeks. Primarily used for the management of knee osteoarthritis, this treatment aims to restore the lubricating and cushioning properties of the synovial fluid in the joint. The Single-Injection Regimen offers an alternative approach to viscosupplementation with the convenience of a one-time injection. This product is formulated with a high concentration of hyaluronic acid and often includes cross-linking agents that enhance the durability and longevity of the treatment within the joint. The Three-Injection Regimen is a widely adopted viscosupplementation treatment that involves a series of three hyaluronic acid injections. These are typically administered one week apart and are designed to supplement the viscous properties of synovial fluid in the joint space. The primary goal of this treatment is to relieve pain and enhance mobility in patients with osteoarthritis. The three-injection regimen strikes a balance between the more extensive five-injection course and the single-injection alternative, offering a middle ground in terms of treatment commitment and duration of symptom relief.
Source: Growing preference for non-animal-based hyaluronic acid as it eliminates hypersensitivity reaction risks
Animal-based sources have been the primary means of obtaining hyaluronic acid for viscosupplementation. Animal-based sources utilize tissues from rooster combs, which are rich in hyaluronic acid or are extracted from other avian tissues. Non-animal-based hyaluronic acid is produced through bacterial fermentation processes. Genetically modified strains of bacteria, such as Streptococcus zooepidemicus, are used to biosynthesize high-purity HA. Non-animal HA is considered safe and effective, eliminating the risks associated with avian proteins that can cause hypersensitivity reactions. Additionally, non-animal-based HA has been gaining popularity due to ethical considerations and consistency in production.
Applications: Evolving applications of viscosupplementation treatment for knee osteoarthritis
Hyaluronic acid is directly injected into the affected joint in the viscosupplementation treatment for hand osteoarthritis. This treatment is used when traditional non-surgical treatments such as pain medications and physical therapy have not provided adequate relief. The main benefit of viscosupplementation for hand osteoarthritis lies in its pain reduction and, hence, improvement in function and quality of life. Viscosupplementation is a proven therapeutic measure to alleviate pain and improve functionality in patients with hip osteoarthritis, particularly those not responding to conventional treatments. The procedure for the hip joint is more complex, often requiring ultrasound or X-ray guidance due to the hip's deep-seated nature. A key advantage of viscosupplementation in hip osteoarthritis is its superior safety profile compared to long-term use of non-steroidal anti-inflammatory drugs (NSAIDs). Knee osteoarthritis is the most common application for viscosupplementation since the knee is a major weight-bearing joint and, therefore, is highly susceptible to wear and tear. The viscosupplementation procedure aims to restore the natural properties of the synovial fluid lost to knee osteoarthritis.
End-use: Proliferating utilization of viscosupplementation treatment in orthopedic clinics/ambulatory surgical centers (ASCs)
Hospitals represent a significant end-use sector for viscosupplementation, a therapeutic option for patients suffering from osteoarthritis, particularly in the knee joint. As comprehensive medical facilities with a multidisciplinary approach, hospitals are pivotal in providing this minimally invasive procedure. Viscosupplementation involves the intra-articular injection of hyaluronic acid to lubricate the joint, alleviate pain, and improve mobility. Orthopedic clinics and Ambulatory Surgical Centers (ASCs) are specialized end-use settings where viscosupplementation is frequently administered. These centers are predominantly focused on musculoskeletal health, making them highly adept at providing targeted therapies like viscosupplementation. The convenience, efficiency, and typically lower costs associated with ASCs make them an attractive option for patients seeking outpatient care.
Regional Insights
The market is evolving in the Americas owing to the growing incidence of osteoarthritis, high healthcare expenditure, increasing preference for minimally invasive procedures, and widespread availability of several FDA-approved HA products. Advanced healthcare systems, increased awareness about osteoarthritis treatment options, and supportive regulatory frameworks are encouraging the growth of the viscosupplementation market in Europe. The Middle East and Africa viscosupplementation market is growing with improving availability and affordability of treatment and the prevalence of competitive treatment modalities for osteoarthritis. The Asia Pacific region represents significant demand for viscosupplementation due to high osteoarthritis prevalence, expanding healthcare infrastructure, and increasing accessibility to advanced osteoarthritis treatments. Besides, ongoing research to improve the efficacy of viscosupplementation therapy is anticipated to propel the demand for the viscosupplementation market globally.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Viscosupplementation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Viscosupplementation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Viscosupplementation Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Anika Therapeutics, Inc., Avanos Medical, Inc., Bausch Health Companies Inc., Bioventus LLC, Contipro A.S., DePuy Synthes by Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Ferring B.V., Fidia Farmaceutici S.p.A., Gentex Pharma, LLC, LG Chem Ltd., Lifecore Biomedical, LLC, Quimfa S.A., Regen Lab SA, Sanofi S.A., Seikagaku Corporation, Smith & Nephew PLC, Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zimmer Biomet.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Viscosupplementation Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Viscosupplementation Market?
3. What are the technology trends and regulatory frameworks in the Viscosupplementation Market?
4. What is the market share of the leading vendors in the Viscosupplementation Market?
5. Which modes and strategic moves are suitable for entering the Viscosupplementation Market?